{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":27,"n_cols":5,"rows_kept":27,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[14,2,14,3],[15,2,15,3],[19,2,19,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910139986703321"]
[null,null,"Titolo",null,"Carbohydrate-based vaccines and immunotherapies [[electronic resource] /] / edited by Zhongwu Guo, Geert-Jan Boons"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, N.J. ; ; Oxford, [UK], : Wiley, c2009"]
[null,null,"ISBN",null,"1-282-36851-6"]
[{"$nulls":4},"9786612368516"]
[{"$nulls":4},"0-470-47328-2"]
[{"$nulls":4},"0-470-47327-4"]
[null,null,"Descrizione fisica",null,"1 online resource (436 p.)"]
[null,null,"Collana",null,"Wiley series in drug discovery and development"]
[null,null,"Disciplina",null,"616.07/9"]
[{"$nulls":4},"616.079"]
[null,null,"Soggetti",null,"Carbohydrates - Immunology"]
[{"$nulls":4},"Vaccines"]
[{"$nulls":4},"Glycoconjugates - Immunology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"CARBOHYDRATE-BASED VACCINES AND IMMUNOTHERAPIES; CONTENTS; Preface; Contributors; 1 Glycobiology and Immunology; 1.1 Introduction; 1.2 Glycobiology; 1.2.1 Glycosylation-Is It Worth the Cost?; 1.2.2 Glycan Biosynthesis-A Dauntingly Complex Process; 1.2.3 Glycoproteins; 1.2.4 Lipid-Based Glycans; 1.2.5 Polysaccharides: Glycosaminoglycans and Bacterial Capsular Components; 1.3 The Immune System; 1.3.1 Introductory Comments; 1.3.2 Overview of the Immune System; 1.3.3 Glycoimmunobiology; 1.3.4 Interplay between Glycosylation and Sugars: a Two-Way Street; 1.4 Carbohydrate Antigens"]
[{"$nulls":4},"1.4.1 Carbohydrate Antigens in Humans1.4.2 Carbohydrates and Pathogens; 1.4.3 Carbohydrate-Based Vaccines; 1.4.4 Concluding Comments: Building on Success; Acknowledgment; References; 2 Preparation of Glycoconjugate Vaccines; 2.1 Introduction; 2.2 Capsular Polysaccharide-Protein Conjugates; 2.2.1 Haemophilus influenzae Type b; 2.2.2 Streptococcus pneumoniae; 2.2.3 Neisseria meningitidis; 2.2.4 Salmonella typhi Vi; 2.2.5 Group B Streptococcus; 2.2.6 Staphylococcus aureus Types 5 and 8; 2.3 Lipopolysaccharide (LPS) and Lipooligosaccharide (LOS) Conjugates; 2.3.1 Escherichia coli O157"]
[{"$nulls":4},"2.3.2 Vibrio cholerae O1 and O1392.3.3 Shigella dysenteriae Type 1, sonnei and flexneri 2a; 2.3.4 Neisseria meningitidis and Nontypeable "]
[{"$nulls":4},"Haemophilus influenzae; 2.4 Total Synthetic Glycoconjugate Vaccines; References; 3 Adjuvants for Protein- and Carbohydrate-Based Vaccines; 3.1 Introduction; 3.2 Initiation and Stimulation of Adaptive Responses; 3.3 \"Old\" Adjuvants and Formulations; 3.3.1 Aluminum; 3.3.2 Emulsions; 3.3.3 Saponins, QS21, and ISCOMS; 3.3.4 Liposomes and Microparticles; 3.3.5 Antigen/Formulation Targeting; 3.3.6 Induction of CD8 CTLs with Soluble Antigens"]
[{"$nulls":4},"3.4 Renaissance of Innate Immunity3.4.1 Toll-Like Receptors: Agonists and Roles; 3.4.2 Non-TLRs Innate Receptors; 3.4.3 Other Receptors Involved in Antigen Capture and Recognition; 3.5 From Basic Research to Practical Applications: Identification of New Adjuvants; 3.5.1 TLR Synthetic Agonists; 3.5.2 Combination of PRR Agonists; 3.6 Adjuvants for Carbohydrate-Based Vaccines; 3.6.1 Td and Ti B-Cell Responses; 3.6.2 Adjuvants for \"Free\" Polysaccharides (Ti Antigens); 3.6.3 Adjuvants for Glycoconjugate Vaccines (T-Dependent Antigens)"]
[{"$nulls":4},"3.7 Combinations of Adjuvants: Preclinical and Clinical Developments3.8 Immunomodulation of Existing Responses: Adjuvants for Therapeutic Vaccines; 3.9 Take Another Route; 3.9.1 Adjuvants for Mucosal Immunization; 3.9.2 Epidermal or Intradermal Routes; 3.10 Practical Aspects of Adjuvant Development; 3.10.1 Regulatory Aspects; 3.10.2 Safety versus Efficacy: Risk-Benefit Ratio; 3.11 Preclinical Models Used in Adjuvant Development; 3.11.1 Animal Models; 3.11.2 In vitro Models; 3.12 Conclusions and Perspectives; Acknowledgment; References; 4 Carbohydrate-Based Antibacterial Vaccines"]
[{"$nulls":4},"4.1 Introduction"]
[null,null,null,"Sommario/riassunto","The fundamental science and the latest developments in carbohydrate-based vaccines The relatively new field of glycoimmunology has emerged from the marriage of glycobiology and immunology, in recognition of the important role carbohydrates play as antigenic determinants. Carbohydrate-Based Vaccines and Immunotherapies comprehensively reviews the state of this exciting field, offering a single source for both the fundamental science and the latest developments. With contributions by leading experts, this resource covers the design, synthesis, evaluation, and applications of va"]